TABLE 2.
Incidence of adverse events 0–14 h after glibenclamide or placebo.
| Adverse event | Glibenclamide-CGRP | Placebo-CGRP |
| Fatigue | 11 | 4 |
| Flushing | 20 | 20 |
| Warm sensation | 19 | 20 |
| Yawn urge | 2 | 1 |
| Thirst | 5 | 0 |
| Neck stiffness | 3 | 4 |
| Palpitation | 18 | 17 |
Official websites use .gov
A
.gov website belongs to an official
government organization in the United States.
Secure .gov websites use HTTPS
A lock (
) or https:// means you've safely
connected to the .gov website. Share sensitive
information only on official, secure websites.